These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 9553173

  • 1. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin.
    Behr TM, Jenner N, Radetzky S, Béhe M, Gratz S, Yücekent S, Raue F, Becker W.
    Eur J Nucl Med; 1998 Apr; 25(4):424-30. PubMed ID: 9553173
    [Abstract] [Full Text] [Related]

  • 2. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
    Behr TM, Jenner N, Béhé M, Angerstein C, Gratz S, Raue F, Becker W.
    J Nucl Med; 1999 Jun; 40(6):1029-44. PubMed ID: 10452322
    [Abstract] [Full Text] [Related]

  • 3. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
    Behr TM, Béhé M, Angerstein C, Gratz S, Mach R, Hagemann L, Jenner N, Stiehler M, Frank-Raue K, Raue F, Becker W.
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
    [Abstract] [Full Text] [Related]

  • 4. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
    Behr TM, Béhé MP.
    Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
    [Abstract] [Full Text] [Related]

  • 5. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M, Behr TM.
    Biopolymers; 2002 Apr; 66(6):399-418. PubMed ID: 12658727
    [Abstract] [Full Text] [Related]

  • 6. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy.
    de Jong M, Bakker WH, Bernard BF, Valkema R, Kwekkeboom DJ, Reubi JC, Srinivasan A, Schmidt M, Krenning EP.
    J Nucl Med; 1999 Dec; 40(12):2081-7. PubMed ID: 10616889
    [Abstract] [Full Text] [Related]

  • 7. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM, Wulst E, Radetzky S, Blumenthal RD, Dunn RM, Gratz S, Rave-Fränk M, Schmidberger H, Raue F, Becker W.
    Cancer Res; 1997 Dec 01; 57(23):5309-19. PubMed ID: 9393755
    [Abstract] [Full Text] [Related]

  • 8. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas.
    Reubi JC, Waser B.
    Int J Cancer; 1996 Sep 04; 67(5):644-7. PubMed ID: 8782652
    [Abstract] [Full Text] [Related]

  • 9. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.
    Béhé M, Becker W, Gotthardt M, Angerstein C, Behr TM.
    Eur J Nucl Med Mol Imaging; 2003 Aug 04; 30(8):1140-6. PubMed ID: 12768330
    [Abstract] [Full Text] [Related]

  • 10. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma.
    Kwekkeboom DJ, Bakker WH, Kooij PP, Erion J, Srinivasan A, de Jong M, Reubi JC, Krenning EP.
    Eur J Nucl Med; 2000 Sep 04; 27(9):1312-7. PubMed ID: 11007512
    [Abstract] [Full Text] [Related]

  • 11. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
    Stein R, Juweid M, Mattes MJ, Goldenberg DM.
    Cancer Biother Radiopharm; 1999 Feb 04; 14(1):37-47. PubMed ID: 10850286
    [Abstract] [Full Text] [Related]

  • 12. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
    Hosono M, Hosono MN, Kraeber-Bodéré F, Devys A, Thédrez P, Fiche M, Gautherot E, Barbet J, Chatal JF.
    J Nucl Med; 1998 Sep 04; 39(9):1608-13. PubMed ID: 9744353
    [Abstract] [Full Text] [Related]

  • 13. [The use of a new analogue DGlu-Octagastrin in scintigraphy of medullary thyroid carcinoma].
    Kosowicz J, Czepczyński R, Ziemnicka K, Gryczyńska M, Sowiński J.
    Endokrynol Pol; 2006 Sep 04; 57(4):427-30. PubMed ID: 17006848
    [Abstract] [Full Text] [Related]

  • 14. Expression of the cholecystokinin 2-receptor in normal human thyroid gland and medullary thyroid carcinoma.
    Blaker M, de Weerth A, Tometten M, Schulz M, Höppner W, Arlt D, Hoang-Vu C, Dralle H, Terpe H, Jonas L, von Schrenck T.
    Eur J Endocrinol; 2002 Jan 04; 146(1):89-96. PubMed ID: 11751073
    [Abstract] [Full Text] [Related]

  • 15. Comparative biodistribution of 12 ¹¹¹In-labelled gastrin/CCK2 receptor-targeting peptides.
    Laverman P, Joosten L, Eek A, Roosenburg S, Peitl PK, Maina T, Mäcke H, Aloj L, von Guggenberg E, Sosabowski JK, de Jong M, Reubi JC, Oyen WJ, Boerman OC.
    Eur J Nucl Med Mol Imaging; 2011 Aug 04; 38(8):1410-6. PubMed ID: 21461732
    [Abstract] [Full Text] [Related]

  • 16. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours.
    von Guggenberg E, Dietrich H, Skvortsova I, Gabriel M, Virgolini IJ, Decristoforo C.
    Eur J Nucl Med Mol Imaging; 2007 Aug 04; 34(8):1209-18. PubMed ID: 17308920
    [Abstract] [Full Text] [Related]

  • 17. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen.
    Juweid M, Sharkey RM, Behr T, Swayne LC, Rubin AD, Hanley D, Herskovic T, Markowitz A, Siegel J, Goldenberg DM.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5946s-5951s. PubMed ID: 7493375
    [Abstract] [Full Text] [Related]

  • 18. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma.
    Kosowicz J, Mikołajczak R, Czepczyński R, Ziemnicka K, Gryczyńska M, Sowiński J.
    Cancer Biother Radiopharm; 2007 Oct 01; 22(5):613-28. PubMed ID: 17979564
    [Abstract] [Full Text] [Related]

  • 19. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors.
    Reubi JC, Schaer JC, Waser B.
    Cancer Res; 1997 Apr 01; 57(7):1377-86. PubMed ID: 9102227
    [Abstract] [Full Text] [Related]

  • 20. Imaging tumors with peptide-based radioligands.
    Behr TM, Gotthardt M, Barth A, Béhé M.
    Q J Nucl Med; 2001 Jun 01; 45(2):189-200. PubMed ID: 11476170
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.